Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) released its fiscal second-quarter results for the three and six months ended September 30, 2026, posting sharply higher protein sales revenue while reporting a wider net loss. The company simultaneously announced a $4.2 million loan from an entity related to a director to bolster working capital. With cash of just $1.0 million and negative working capital of $15.0 million on the balance sheet, investors may be watching the company's liquidity position and broader financing plans closely.

Key Points

  • Burcon NutraScience Corporation (TSX: BU / OTCQB: BRCNF) reported fiscal Q2 2027 financial results on November 16, 2026.
  • Quarterly revenue reached $1,040,829, a approximately 191% increase over the prior year comparable period, driven by protein sales growth at the Galesburg production facility.
  • A $4.2 million loan maturing November 16, 2027, bearing 15% annual interest, was entered into with the James P Pekar Family Endowment Trust, a related party.
  • Investors may be watching the company's ability to secure additional short- and long-term financing, with no assurance such financing will be available on acceptable terms.

Protein Sales Drive Burcon's Strongest Revenue Growth in Recent Quarters

Burcon generated revenue of $1,040,829 for the three months ended September 30, 2026, and $2,317,041 for the six-month period, representing approximately 191% and 231% increases, respectively, over the prior year comparable periods. The company attributes this growth to ramping commercial production at its Galesburg production facility. The release states that infrastructure challenges and plant reliability issues constrained shipments during the quarter, though management indicated production volumes had recovered and accelerated since quarter-end.

Net Loss Widens and Negative Working Capital Signals Liquidity Pressure

For the six months ended September 30, 2026, Burcon reported a net loss of $7.9 million, or $0.62 per share, compared with a net loss of $7.0 million, or $0.56 per share, in the prior year period. Net cash used in operating activities was $4.4 million, modestly improved from $4.7 million previously. As of September 30, 2026, the company held $1.0 million in cash and carried negative working capital of $15.0 million, primarily reflecting the current classification of related-party senior secured and short-term loans. The company stated it is evaluating financing options but offered no assurance that additional capital would be available.

Related-Party $4.2M Loan Provides Near-Term Working Capital Relief

To address its working capital requirements, Burcon entered into a loan agreement for up to $4.2 million with the James P Pekar Family Endowment Trust, an entity related to director James Pekar. The loan bears interest at 15% per annum, carries a $7,000 commitment fee, and matures on November 16, 2027. The transaction is classified as a related-party transaction under Multilateral Instrument 61-101, with Burcon relying on an available exemption from minority shareholder approval. The loan was approved by the company's independent directors, with the interested director abstaining.